You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 299 No. 9, March 5, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Research Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (19)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Pain
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Commercial Features of Placebo and Therapeutic Efficacy

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: It is possible that the therapeutic efficacy of medications is affected by commercial features such as lower prices. Because such features influence patients' expectations,1 they may play an unrecognized therapeutic role by influencing the efficacy of medical therapies, especially in conditions associated with strong placebo responses.2-3 To investigate this possibility, we studied the effect of price on analgesic response to placebo pills.

Methods

In 2006 we recruited 82 healthy paid volunteers in Boston, Massachusetts, using an online advertisement. Each participant was informed by brochure about a (purported) new opioid analgesic approved by the Food and Drug Administration; it was described as similar to codeine with faster onset time, but it was actually a placebo pill. After randomization, half of the participants were informed that the drug had a regular price of $2.50 per pill and half that the price had been discounted to $0.10 per pill (no reason . . . [Full Text of this Article]

Rebecca L. Waber, BS
Massachusetts Institute of Technology
Cambridge, Massachusetts

Baba Shiv, PhD
Stanford University
Stanford, California

Ziv Carmon, PhD
INSEAD
Singapore

Dan Ariely, PhD
ariely@mit.edu
Massachusetts Institute of Technology



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

QUESTION 1
Bradley and Finlay
Arch. Dis. Child. 2009;94:555-556.
FULL TEXT  

CLINICAL CONSEQUENCES OF GENERIC SUBSTITUTION OF LAMOTRIGINE FOR PATIENTS WITH EPILEPSY
Boylan et al.
Neurology 2009;72:1876-1877.
FULL TEXT  

Patients' Perceptions Of Generic Medications
Shrank et al.
Health Aff (Millwood) 2009;28:546-556.
ABSTRACT | FULL TEXT  

The art of medicine in treating osteoarthritis: I will please
Bijlsma and Welsing
Ann Rheum Dis 2008;67:1653-1655.
FULL TEXT  

We're Tired of Waiting
Lichtor and Glass
Anesth. Analg. 2008;107:353-355.
FULL TEXT  

Reconceptualising placebo
Moseley
BMJ 2008;336:1086-1086.
FULL TEXT  

What is the placebo worth?
Spiegel and Harrington
BMJ 2008;336:967-968.
FULL TEXT  

All you need to read in the other general journals
BMJ 2008;336:582-583.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.